– CANADA, Montreal – Theratechnologies Inc. (TSX:TH) today announced the appointment of Ms. Sheila M. Frame as a new independent member to its Board of Directors.
“Sheila is a seasoned pharmaceutical executive who brings deep knowledge of the United States and other international markets. Her experience represents a tremendous asset for our Board as the activities of the Company are quickly expanding and as we are preparing to enter the European market,” said Ms. Dawn Svoronos, Chair of the Board, Theratechnologies Inc.
“Her appointment is in line with the announcement we made during our last annual meeting of shareholders in May 2018 to the effect that we would be looking to add new board members given how our Company was growing,” added Ms. Svoronos.
About Sheila Frame
Ms. Frame is currently Vice President and Head Biopharmaceuticals, North America at Sandoz Inc. in the United States. Previously, she successively held the positions of Worldwide General Manager, Immunoscience, Worldwide Commercial Lead, Opdivo® new indications and Biomarker diagnostics, Worldwide Commercial Lead Yervoy from the US and Vice President, specialty business at Bristol-Myers Squibb in Canada. She was also called upon to occupy several senior roles at UCB Inc. and at AstraZeneca in Canada, the US and the Nordics.
Ms. Frame completed the requirements for the Chartered Corporate Director program with the Director’s college in 2006. She also completed a Masters of Business Administration at Concordia University in Montreal and she holds a Bachelor of Arts from York University in Toronto.
Theratechnologies is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV.
For more information : http://www.theratech.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.